Skye Bioscience Inc (SKYE)

$3.29 -0.26 (-7.32%)
Market Cap 101.95M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 488,400
Avg Vol 1,071,630
Day's Range N/A - N/A
Shares Out 30.99M
Stochastic %K 42%
Beta 2.21
Analysts Strong Sell
Price Target $15.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
Multipliers
Multipliers Aug. 25 at 3:40 PM
$SKYE if Nimacimab is shown to have a fewer side effects then it will be a big winner, even if it's weight loss results are sub optimal to current GLP 1s. There are a ton of people who just want to lose a few vanity pounds but don't want to deal with the side effects of glp1s. Also, if it have fewer side effects, it become a potential leader in the maintenance category. One of the downsides of GLP1s is no one wants to be on them forever due to the side effects. But if you come off with them, most gain the weight right back. So there's a ton of money to be made simply as a maintenance therapy as well!
0 · Reply
MissionaryTrader
MissionaryTrader Aug. 23 at 12:14 AM
$SKYE 5am Ventures sold 231, 405 shares in the last 2 days.
1 · Reply
Theflash88
Theflash88 Aug. 22 at 8:24 PM
$SKYE Why down today??
0 · Reply
mvisshortsellersgone
mvisshortsellersgone Aug. 22 at 7:50 PM
$ALT $CRON $MVIS $RR $SKYE MVIS Mega Multi bagger 60x-80x SOON
2 · Reply
rockytoday
rockytoday Aug. 22 at 7:37 PM
$SKYE buy the dip
0 · Reply
YazzJr
YazzJr Aug. 22 at 7:35 PM
$SKYE I said about week or so ago that it was going to bounce between $3 and $3.50 give or take a few cents and so far I am right. I just not sure I see this really finding a big move prior to the results. But who knows maybe it starts running up to the results but are we sure exactly when those results are coming out. They said sometime before the end of the 3rd qtr...so between now and October. We will see, for now it's a hold. Have a good weekend everyone. One day closer to those results.
0 · Reply
DrTechnology
DrTechnology Aug. 22 at 5:31 PM
$ALT $CRON $MVIS $RR $SKYE you’re exposing that you don’t understand growth-stage valuation. Quoting $155K revs is clown math. MVIS is Euro-NCAP validated, in Tier-1 ZF production, and already shipped to the Army. Trailing multiples mean nothing before scale — Tesla once traded at 1,000× sales too. Lmao
1 · Reply
StoppedOut6
StoppedOut6 Aug. 22 at 5:16 PM
$CRON $RR $MVIS $SKYE $ALT MVIS reported $155K revenue last quarter with no guidance for improvement. They are trading over 450x revs I don't wanna ever hear how they're undervalued, lol
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 22 at 4:57 PM
Here are my multi baggers for the next 2-3 months. $CRON mc is less than their lifesaving drug royalties. Ie they will have more money coming in than the entire companys market cap. They also own more assets than their mc. 💥💥🚀🚀 $RR robotics are the future of drink/food service given rising labor market costs. $MVIS beat up beyond undervalued $SKYE: assuming they release data in October $ALT 48 week data will be glorius. VkTx likely best metabolic buyout candidate (buy out offer at 45-50 last year, I expect them to accept 80 if offerred)
1 · Reply
ImHere4Lambos
ImHere4Lambos Aug. 21 at 4:43 PM
To the $SKYE 🚀
0 · Reply
Latest News on SKYE
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 4 days ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 17 days ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 17 days ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 26 days ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 6 weeks ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 3 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 3 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 3 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16, 2025, 7:50 AM EDT - 4 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

Apr 15, 2025, 3:42 PM EDT - 4 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 15, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Apr 14, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 9:58 PM EDT - 5 months ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Mar 14, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 20, 2025, 7:00 AM EST - 6 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Skye Bioscience Announces Participation in February Conferences

Feb 4, 2025, 7:00 AM EST - 7 months ago

Skye Bioscience Announces Participation in February Conferences

MoneyShow's Best Investment Ideas For 2025: Part 8

Feb 3, 2025, 9:20 AM EST - 7 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 8 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10, 2024, 8:32 AM EST - 9 months ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 14, 2024, 7:00 AM EST - 10 months ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:36 PM EST - 10 months ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 7, 2024, 4:01 PM EST - 10 months ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience to Announce Third Quarter 2024 Results

Nov 1, 2024, 7:00 AM EDT - 10 months ago

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Oct 21, 2024, 7:00 AM EDT - 11 months ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Oct 9, 2024, 1:13 PM EDT - 11 months ago

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

RENT SCWO

Skye: Moving Weight Loss Drugs To The Next Level

Sep 4, 2024, 11:26 AM EDT - 1 year ago

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 21, 2024, 10:00 AM EDT - 1 year ago

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 12:40 AM EDT - 1 year ago

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Aug 13, 2024, 2:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 8:30 PM EDT - 1 year ago

Skye Bioscience Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 9, 2024, 5:59 PM EDT - 1 year ago

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Multipliers
Multipliers Aug. 25 at 3:40 PM
$SKYE if Nimacimab is shown to have a fewer side effects then it will be a big winner, even if it's weight loss results are sub optimal to current GLP 1s. There are a ton of people who just want to lose a few vanity pounds but don't want to deal with the side effects of glp1s. Also, if it have fewer side effects, it become a potential leader in the maintenance category. One of the downsides of GLP1s is no one wants to be on them forever due to the side effects. But if you come off with them, most gain the weight right back. So there's a ton of money to be made simply as a maintenance therapy as well!
0 · Reply
MissionaryTrader
MissionaryTrader Aug. 23 at 12:14 AM
$SKYE 5am Ventures sold 231, 405 shares in the last 2 days.
1 · Reply
Theflash88
Theflash88 Aug. 22 at 8:24 PM
$SKYE Why down today??
0 · Reply
mvisshortsellersgone
mvisshortsellersgone Aug. 22 at 7:50 PM
$ALT $CRON $MVIS $RR $SKYE MVIS Mega Multi bagger 60x-80x SOON
2 · Reply
rockytoday
rockytoday Aug. 22 at 7:37 PM
$SKYE buy the dip
0 · Reply
YazzJr
YazzJr Aug. 22 at 7:35 PM
$SKYE I said about week or so ago that it was going to bounce between $3 and $3.50 give or take a few cents and so far I am right. I just not sure I see this really finding a big move prior to the results. But who knows maybe it starts running up to the results but are we sure exactly when those results are coming out. They said sometime before the end of the 3rd qtr...so between now and October. We will see, for now it's a hold. Have a good weekend everyone. One day closer to those results.
0 · Reply
DrTechnology
DrTechnology Aug. 22 at 5:31 PM
$ALT $CRON $MVIS $RR $SKYE you’re exposing that you don’t understand growth-stage valuation. Quoting $155K revs is clown math. MVIS is Euro-NCAP validated, in Tier-1 ZF production, and already shipped to the Army. Trailing multiples mean nothing before scale — Tesla once traded at 1,000× sales too. Lmao
1 · Reply
StoppedOut6
StoppedOut6 Aug. 22 at 5:16 PM
$CRON $RR $MVIS $SKYE $ALT MVIS reported $155K revenue last quarter with no guidance for improvement. They are trading over 450x revs I don't wanna ever hear how they're undervalued, lol
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 22 at 4:57 PM
Here are my multi baggers for the next 2-3 months. $CRON mc is less than their lifesaving drug royalties. Ie they will have more money coming in than the entire companys market cap. They also own more assets than their mc. 💥💥🚀🚀 $RR robotics are the future of drink/food service given rising labor market costs. $MVIS beat up beyond undervalued $SKYE: assuming they release data in October $ALT 48 week data will be glorius. VkTx likely best metabolic buyout candidate (buy out offer at 45-50 last year, I expect them to accept 80 if offerred)
1 · Reply
ImHere4Lambos
ImHere4Lambos Aug. 21 at 4:43 PM
To the $SKYE 🚀
0 · Reply
J_THunder77
J_THunder77 Aug. 21 at 1:56 PM
$SKYE Looking like the beginning of another run up 🚀
0 · Reply
leis5
leis5 Aug. 21 at 1:54 PM
$SKYE LFG!
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Aug. 21 at 1:17 PM
$SKYE very few stocks (<1%) can make a 50-100x moves. Kudos to anyone that got into $ASTS as it was raising capital at $5. But yes. I STRONGLY believe Skye will make a huge move that will ultimately result in life changing growth for some. The 5 way race between NVO/LLY/VKTX/TERN/ALT is essentially creeching to a halt without much to distinguish the 4 ( balance more weight loss = more side effects with AlT being the most tolerated with MASH target) . Skye is going after the combo TX strategy which will likely be the way to go over single agents. Skye offers the added benefit of targeting the adverse effects of Marijuana use which will only grow as trump will likely reschedule Cannibis. A price target of $20-50 immediately after data results is within reach, it all depends on the data, which the company keeps giving us lots of hope!
0 · Reply
nirahl
nirahl Aug. 21 at 12:53 PM
$SKYE https://ir.skyebioscience.com/news-releases/detail/239/skye-bioscience-to-participate-in-upcoming-investment-and-medical-conferences
1 · Reply
Kantus
Kantus Aug. 20 at 3:15 PM
$SKYE
0 · Reply
OC3510
OC3510 Aug. 20 at 12:53 PM
$SKYE This shit Is gonna go crazy if results are good. genuinely life changing money on this one.
1 · Reply
Milano14
Milano14 Aug. 20 at 4:44 AM
$SKYE Institutional ownership at 68.71%. Looks like it’s stabilizing.
0 · Reply
InvestInWhatYouKnow
InvestInWhatYouKnow Aug. 19 at 5:43 PM
$VKTX with their GLP-1 ph2 candidate glitch is one additional feather in the cap of $SKYE with their large molecule CB1 inhibitor ph2 weight loss candidate. The other is the discontinued development of another, $NVO small molecule CB1 inhibitor weight loss candidate. When it come to the BBB, it appears larger is better.
1 · Reply
slayer70
slayer70 Aug. 19 at 4:58 PM
$SKYE Good luck to all here on this board. Hope everyone makes money. I jumped out of this a little while ago to double down on my cannabis investments. I'm happy to exit a second time in the green
0 · Reply
YazzJr
YazzJr Aug. 19 at 4:01 PM
$SKYE Interesting news from Viking Therapautics. Their oral weightloss drug works but, the drop out rate is very high. All SKYE needs to do is show that it's weightloss drug works with out the major side effects. It doesn't even have to work great. Just show it works well enough to be used without the side effects. Anyway here is the link to Viking for those of you interested. https://www.investors.com/news/technology/viking-therapeutics-stock-weight-loss-pill-results
0 · Reply
OC3510
OC3510 Aug. 19 at 3:35 PM
$SKYE How's Institutional ownership looking?
1 · Reply
frandanconia
frandanconia Aug. 19 at 2:10 PM
$SKYE swinging into Sept catalysts and top-line data in Oct. Has room to run.
0 · Reply